Shizuoka Cancer Center News & Topics March 25,2024
The Shizuoka Cancer Center has completed building out the “Integrated Management System for Cancer Genomic Medicine” (the support system for inspection work and report writing for cancer genomic test). After the test trials carried out from April, the full-scale operation of the system is scheduled to launch in July, 2024. The system is supposed to secure the quantity and quality of the information required for implementing the clinical inspection for whole genome analysis. With this system, time required for the test result assessment will be greatly saved.
This system has been developed by Dr. Masakuni Serizawa, the researcher at the Drug Discovery and Development Division, the Shizuoka Cancer Center Research Institute, in collaboration with Fujitsu Japan, Ltd. It enables the result integration of whole genome analysis of cancer patients and RNA sequencing, which is effective in narrowing the critical genes, and the semi-automatic report writing. The report written in this system comprises as much information as possible with simple and comprehensive description of it, all of which is based on the prevision that it will be useful for the years to come when the patient has a recurrence. In addition, through using enormous genomic information accumulated in the database of the system, it will make it possible to utilize it for developing a new treatment method. Dr. Serizawa and his collaborators are aiming at taking the system one step further toward a more user-friendly one than what it is now, utilizing generative AI (artificial intelligence) in the future.
The development of this system has been supported by the Japan Agency for Medical Research and Development (AMED) as one of the national research projects for clinical implementation of whole-genome analysis in which the Shizuoka Cancer Center has participated since 2021.
